Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases is a phase 2, interventional study registered as NCT05742425 by Second Affiliated Hospital, Zhejiang University, School of Medicine, with a registry enrolment figure of 30 participants, started 2023-03 and due to reach its primary completion in 2028-03. Interventions recorded: Serplulimab Combined With FOLFIRI and Bevacizumab. Conditions listed: Unresectable Colon Cancer Peritoneal Metastases; PMMR/Ras/BRAF Wild-type. Primary outcome: Disease-free survival (DFS). Colorectal eligibility wording from the registry: "Colon cancer was confirmed by histology, and its gene detection was pMMR/MSS and RAS/BRAF wild-type". Sites: China. No results are recorded here; the registry entry is the source.